deltatrials
Completed OBSERVATIONAL NCT03753724

IDEAL: Artificial Intelligence and Big Data for Early Lung Cancer Diagnosis Study (IDEAL)

IDEAL: Artificial Intelligence and Big Data for Early Lung Cancer Diagnosis Prospective Study (Phase 2)

Sponsor: Optellum Ltd.

Updated 7 times since 2018 Last updated: Jul 28, 2022 Started: Aug 29, 2018 Primary completion: Mar 31, 2022 Completion: Mar 31, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A observational or N/A phase clinical study on Lung Cancer and Pulmonary Nodule, Multiple, this trial is completed. The trial is conducted by Optellum Ltd. and has accumulated 7 data snapshots since 2018. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Dec 2018 – ~Dec 2020 · 24 months · monthly snapshotRecruiting~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshotUnknown Status~Jan 2021 – ~May 2021 · 4 months · monthly snapshotUnknown Status~May 2021 – ~Sep 2022 · 16 months · monthly snapshotRecruiting~Sep 2022 – ~Jul 2024 · 22 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 22 months · monthly snapshotCompleted

Change History

7 versions recorded
  1. Sep 2024 — Present [monthly]

    Completed

  2. Jul 2024 — Sep 2024 [monthly]

    Completed

  3. Sep 2022 — Jul 2024 [monthly]

    Completed

    Status: RecruitingCompleted

  4. May 2021 — Sep 2022 [monthly]

    Recruiting

    Status: Unknown StatusRecruiting

  5. Jan 2021 — May 2021 [monthly]

    Unknown Status

Show 2 earlier versions
  1. Dec 2020 — Jan 2021 [monthly]

    Unknown Status

    Status: RecruitingUnknown Status

  2. Dec 2018 — Dec 2020 [monthly]

    Recruiting

    First recorded

Aug 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Optellum Ltd.
  • University of Oxford
Data source: University of Oxford

For direct contact, visit the study record on ClinicalTrials.gov .